Shares of Arena Pharmaceutical (ARNA +1.8%) and Vivus (VVUS +3.3%) both gain today, after...

Shares of Arena Pharmaceutical (ARNA +1.8%) and Vivus (VVUS +3.3%) both gain today, after Leerink Swann resumes coverage on both with an Outperform rating. The firm gives VVUS a price target range of $19 - $20.

From other sites
Comments (2)
  • user418
    , contributor
    Comments (264) | Send Message
    Leerink Swann reports from DREAMLAND that VIVUS will rise 30% plus from $13.45 to $20.00. If one wants a 30% rise your chances are much better buying ARNA !!!!!!!!!!!!!
    6 Feb 2013, 04:38 PM Reply Like
  • nomis_simon
    , contributor
    Comments (162) | Send Message
    Yeah, the general public stopped paying attention to Areniacs after approval didn't get you to $15-$20 like you all foretold. Real money is following Vivus again as they're getting stronger and building steam leading up to announcements regarding Stendra partnerships etc.


    Can't wait for the EMA's decision on Belviq. I hope it'll shut some of you guys up a bit, but I know you'll just cling to a new fallacy.
    6 Feb 2013, 10:30 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs